PLSEPulse Biosciences Inc

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences Management is...

Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced its Co-Chairmen of the Board, Robert Duggan...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced plans to participate in the upcoming BofA...

Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05...

Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +15.63% and -19.80%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?